Compare PRSO & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSO | APM |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.0M |
| IPO Year | 2001 | 2018 |
| Metric | PRSO | APM |
|---|---|---|
| Price | $0.89 | $0.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | ★ 488.1K | 66.2K |
| Earning Date | 03-18-2026 | 10-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,001,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $35.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 2.15 | N/A |
| 52 Week Low | $0.52 | $0.69 |
| 52 Week High | $2.37 | $4.47 |
| Indicator | PRSO | APM |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | 41.72 |
| Support Level | $0.83 | $0.80 |
| Resistance Level | $0.89 | $0.88 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 47.78 | 39.89 |
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.